Cognition - Articles - Page 2 | CARLAT PUBLISHING

CLINICAL UPDATE

Cognitive Remediation: A Game Changer for Clients with Mental Illness

September 12, 2023

Alice Saperstein, PhD. Assistant Professor, Department of Psychiatry, Columbia University Irving Medical Center, New York, NY. Dr. Saperstein has disclosed that she receives book royalties from Oxford University Press.
The editors have reviewed this article and found no evidence of bias in this educational activity.

Tips for integrating cognitive remediation into your practice.

Research Update

Lurasidone vs Quetiapine in Bipolar Depression

September 1, 2023

Kate J. Travis, MD

Kate Travis, MD. Dr. Travis has no financial relationships with companies related to this material.

Both these medications work in bipolar depression, but this analysis compared them head-to-head for a different primary outcome: Cognition in bipolar disorder.

Research Update

Adjuvant Clonidine for Mania

March 8, 2023

Michael Posternak, MD.

Michael Posternak, MD. Dr. Posternak has no financial relationships with companies related to this material.

Clonidine was a promising therapy for mania in the 1980s, but the ball got dropped. This study picks that up with a modern-day randomized-controlled design.

Clinical Update

Four Controversial Diagnoses in Psychiatry: Are They Valid?

March 8, 2023

Chris Aiken, MD and Tony Thrasher, DO, DFAPA

Chris Aiken, MD. Editor-in-Chief of TCPR. Practicing psychiatrist. Winston-Salem, NC.

Tony Thrasher, DO, DFAPA. Immediate past president, American Association for Emergency Psychiatry (AAEP). Medical Director of Crisis Services, Milwaukee County Behavioral Health. Milwaukee, WI. Clinical Associate Professor, Medical College of Wisconsin. Milwaukee, WI.

Dr. Aiken and Dr. Thrasher have no financial relationships with companies related to this material.

From Google to TikTok, patients are diagnosing themselves with disorders that didn’t make it in the DSM. We take an open look at the validity of sensory processing disorder, slow cognitive speed, “ring of fire” ADHD, and complex PTSD.

Throwback Thursday: Do Antipsychotics Improve Cognition?

October 6, 2022

Chris Aiken, MD and Kellie Newsome, PMHNP

Are newer antipsychotics better for cognition than their older, typical forbearers?

RESEARCH UPDATE

Trazodone Probably Not Effective for Dementia

October 1, 2022

Susan L. Siegfreid, MD

Susan L. Siegfreid, MD. Dr. Siegfreid, author of this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

This study revealed no signal that trazodone protects against neurodegeneration.

How to Interview the Older Patient

August 29, 2022

Stephanie Collier, MD and Rehan Aziz, MD.

The expanding population of older adults has created a need for all clinicians to participate in their care. Interviewing techniques require adaptation in older adults, such as accounting for hearing or vision impairment and speaking slowly and clearly. This podcast will cover additional factors to consider when evaluating older patients.

RESEARCH UPDATE

Vyvanse for Sluggish Cognitive Tempo in ADHD

August 1, 2022

Thomas Jordan, MD

Thomas Jordan, MD. Dr. Jordan, author for this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

This study won’t tell us if “sluggish cognitive tempo” is a valid disorder, but it does show how Vyvanse works in this controversial subtype of ADHD.
Research Update

RESEARCH UPDATE

Anticholinergic-Associated Cognitive Impairment in Schizophrenia

April 5, 2022

Brian Miller, MD, PhD, MPH.

Brian Miller, MD, PhD, MPH. Dr. Miller has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Antipsychotics, benztropine, and antidepressants have anticholinergic properties that can impair cognition. A study takes a deep dive into the magnitude of the risk of dementia in schizophrenia.

In the News: Aducanumab (Aduhelm)

November 5, 2021

Rehan Aziz, MD.

Rehan Aziz, MD. Associate professor of psychiatry and neurology, Rutgers Robert Wood Johnson Medical School. Dr. Aziz has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

When the FDA approved aducanumab (Aduhelm) in Alzheimer dementia, the decision came with a heavy dose of controversy. Rehaz Aziz, MD, considers where this novel therapy fits in practice.